GLP-1s in Hip and Knee Arthroplasty

Sponsor
Nova Scotia Health Authority
Study ID
NCT07755085
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Arthritis
  • GLP - 1
  • Obesity & Overweight

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • GLP-1 Receptor Agonists + Behavioral modification — DRUG
    At least 6 months of preoperative semaglutide and structured behavioural modification
  • Behavioral + placebo — BEHAVIORAL
    Structured behavioural modification - diet, exercise, counselling and placebo medication

Study Details

The number of people living with hip and knee arthritis continues to grow. A large amount of these people are also overweight and diagnosed with obesity. Obesity leads to more stress on hip and knee joints, causing them to wear out sooner. This process is called arthritis. When arthritis gets worse, the joints often need to be replaced due to pain and poor mobility. Very heavy patients often have other health problems that can impair the ability to manage arthritis. Excess weight and health problems can change the way heavy patients recover after surgery, leading to a greater risk of complications. A new type of medicine might be able to improve how obese patients manage their hip and knee pain, as well as improve outcomes after surgery. This type of medicine is called a GLP-1. Investigators will study 2 groups, with one receiving the medicine while the other does not. The goal is to understand how these medications work in the time leading up to surgery and in the early postoperative recovery phase. If these medications help, it may improve the care of high risk obese patients.

Key Dates

First listed
Aug 10, 2026
Start date
Oct 1, 2026
Status verified
Jul 2026
Primary completion
Jun 1, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo Medication
    Patients administered placebo medication for at least 6 months preoperatively
  • Experimental: Study medication group
    Patients receive at least 6 months of study group medication preoperatively

Primary Outcome Measure

Incidence of Wound Complication after Joint Arthroplasty [ Time Frame: 90 days ]

Central Contacts

Related Studies